Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjects withmetastaticsubjects mustcellradiation
  Phrases that lowered it: hiv infectedaminotransferaseartulnpharmacokinetics
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Maximum age: 100 (lowers risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Keywords listed: 27 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 24.2% (raises risk) · Drug's FDA history
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma NCT06790966 · started 2025 · scored riskier than 62% of active trials terminated
• Pembrolizumab in Combination With CRT for LA-SCCHN NCT02586207 · started 2015 · scored riskier than 77% of active trials completed
• Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) NCT03386357 · started 2018 · scored riskier than 78% of active trials terminated
• Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease NCT04685499 · started 2021 · scored riskier than 87% of active trials terminated
• CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04633278 · started 2021 · scored riskier than 87% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.